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ABSTRACT 
 
T-cell acute lymphoblastic leukemia (T-ALL) is a hematological cancer that mainly affects 
children. Although current treatments are effective, they originate significant long-term side-
effects and significant number of relapses occur. Both microenvironmental and cell-
autonomous cues contribute to T-ALL progression. IL-7 is an essential cytokine that has 
been shown to promote survival and proliferation of T-ALL cells by activating the PI3K/Akt 
pathway. Notch and CK2 have been implicated in transformation and survival of T-ALL cells 
by downregulating or functionally inactivating PTEN protein, a tumor suppressor and 
negative regulator of PI3K/Akt pathway.  
In the present thesis, two main objectives were defined: to establish the relative importance 
of two proteins, GSK3β and FOXO3a, which are negatively regulated by the PI3K/Akt 
pathway, in IL-7-mediated proliferation and viability of T-ALL cells; and to assess the 
therapeutic potential of combined Notch and CK2 inhibition in the regulation of the tumor 
suppressor PTEN. Both objectives can contribute to the rational definition of new therapeutic 
targets and the development of novel treatment strategies. 
To accomplish the first task, lentiviral vectors were constructed bearing constitutively active 
mutants of GSK3β and FOXO3a (GSK3β.S9A and FOXO3a.A3). Preliminary data suggest 
that downregulation of FOXO3a activity may be mandatory for IL-7 to exert its effects upon 
leukemia cells. T-ALL cells transduced with this mutant show decreased viability and IL-7 
stimulation cannot rescue the viability to the control levels. 
To accomplish the second task, PTEN+ cell lines were incubated with the γ-secretase 
inhibitor (Notch inhibitor) DAPT, the CK2 inhibitors DRB or TBB, or with both. Our results 
show that the combined use of γ-secretase and CK2 inhibitors can affect the cell size, cell 
number and proliferation of T-ALL cell lines in a cooperative manner.  
 
RESUMO 
 
Introdução: A leucemia linfoblástica aguda de células T (LLA-T) é um cancro 
hematológico que afecta especialmente crianças até 5 anos de idade, sendo um dos tipos 
de cancro mais comum nesta faixa etária. Esta doença caracteriza-se pela expansão clonal 
descontrolada de linfócitos T imaturos na medula óssea e timo, que extravasam para o 
sangue periférico e invadem outros órgãos. Os tratamentos actualmente existentes têm uma 
eficácia considerável: em média, 70% dos doentes apresentam-se livres de doença 5 anos 
após o tratamento. No entanto, a percentagem de recidivas (cujo prognóstico é 
extremamente reservado) e as complicações a longo prazo devido à elevada toxicidade dos 
tratamentos, tornam premente a necessidade de novas terapias, mais específicas e 
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eficazes. Nesse sentido, as vias de transdução de sinal que promovem a proliferação e 
sobrevivência das células tumorais constituem promissores alvos terapêuticos. 
São conhecidas várias causas para este tipo de leucemia: factores hereditários, exposição 
excessiva a radiação ou químicos, entre outros. Além de factores intrínsecos à célula 
maligna, os factores microambientais desempenham um papel fundamental no 
estabelecimento do tumor. A IL-7 é uma citocina essencial para a linfopoiése, funcionando 
como factor de crescimento e sobrevivência para células T normais. Contudo, as células T 
tumorais também beneficiam da IL-7, proliferando significativamente em resposta a esta 
citocina..  
A IL-7 utiliza a via Jak/STAT para transdução de sinal pelo IL-7R. Após activação do 
receptor, são imediatamente activadas as cinases de tirosina Jak1 e Jak3 e 
subsequentemente as STATs. As Jak não têm apenas as STAT como substratos mas 
também outros intervenientes essenciais em vias de sinalização como a PI3K na via 
PI3K/Akt. A família de cinases PI3K está envolvida na síntese de fosfatidilinositóis 
trifosfatados (PIP3) na membrana. A síntese de PIP3 recruta as cinases PDK e Akt, com a 
consequente activação de Akt por PDK. A Akt é a cinase de serina/treonina efectora da via 
PI3K/Akt, tendo numerosos alvos envolvidos na regulação de diferentes processos celulares 
A fosforilação catalisada por esta cinase pode ser activadora ou repressora, levando a que, 
de uma forma geral, a proliferação celular e a sobrevivência sejam aumentadas. Exemplos 
de proteínas inactivadas por Akt incluem membros da família Forkhead e GSK3. É frequente 
esta via de sinalização estar hiper-activada em tumores, incluindo LLA-T. 
O factor de transcrição FOXO3a (membro da família Forkhead) é inactivado em resultado 
da fosforilação catalisada por Akt. FOXO3a tem sido implicado como tendo um papel 
protector em processos como envelhecimento, neurodegeneração e cancro. FOXO3a 
promove a expressão de Gadd45, TRAIL, Bim, Noxa, FasL e p27Kip1, entre outros indutores 
de apoptose e inibidores do ciclo celular. Após estimulação com IL-7, ocorre a activação da 
via PI3K/Akt e subsequente fosforilação/inactivação de FOXO3a. GSK3β é uma cinase de 
serina/treonina que também se possui diversos substratos A fosforilação mediada por 
GSK3β origina a activação de proteínas pró-apoptóticas (Bax, Bim, p53) e inactivação e/ou 
degradação de proteínas anti-apoptóticas e promotoras do ciclo celular (Mcl-1, CREB, 
Ciclina D1, c-Myc). A activação da via PI3K/Akt resultante da estimulação com IL-7 resulta 
na fosforilação e consequente inactivação de GSK3β. No entanto, não se sabe se qualquer 
um destes dois processos (inactivação de FOXO3a e inactivação de GSK3β) é necessário 
para que a IL-7 funcione como citocina indutora de viabilidade e proliferação das células 
LLA-T. 
PTEN, um supressor tumoral, é o principal regulador negativo da via PI3K/Akt. Trata-se de 
uma fosfatase de lípidos cuja função é directamente antagónica da de PI3K. Como tal, este 
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gene sofre frequentemente mutações ou deleções em muitos tipos de cancro. Em LLA-T é 
frequente encontrar-se uma baixa actividade de PTEN devido a mecanismos de regulação 
transcricional, mediados por Notch, e pós-traducional, mediados por CK2. 
A via de sinalização Notch está implicada em eventos como diferenciação, proliferação e 
apoptose, sendo fundamental durante a embriogénese. Existem diversos receptores Notch e 
também diversos ligandos. Canonicamente, após a ligação do ligando, Notch é clivado por 
TACE e pelo complexo γ-secretase. Esta última clivagem liberta dentro das células, a forma 
activa do receptor Notch (NICD), que funciona como factor de transcrição. São transcritos, 
directa e indirectamente, genes como Hes1, Hey, c-Myc ou Ciclina D1, todos eles implicados 
num aumento da sobrevivência e proliferação. A sinalização alterada de Notch tem sido 
descrita em diferentes tipos de cancro. Em LLA-T, mais de 50% dos casos têm mutações 
activadoras de Notch1, ou seja, mutações em NOTCH que levam a uma maior 
processividade do complexo γ-secretase. A activação de Notch conduz a um silenciamento 
transcricional de PTEN, por intermédio de Hes1, tendo como consequência uma sobre-
activação da via PI3K/Akt. 
A proteína CK2, é uma cinase de serina/treonina com um enorme leque de substratos na 
célula. Devido à extensa diversidade de substratos, a sua regulação é complexa e pouco 
compreendida. No entanto, um aumento de actividade de CK2 tem sido implicado na 
transformação maligna e aumento de agressividade do tumor. Em leucemia, foi 
demonstrado que a actividade de CK2 pode levar tanto a uma degradação aumentada de 
supressores tumorais, mas também a uma estabilização de proteínas em formas inactivas. 
CK2 está frequentemente sobre-activa em células primárias de doentes com LLA-T, 
promovendo a estabilização e inactivação de PTEN. Consequentemente, embora as células 
leucémicas apresentem elevados níveis de expressão de PTEN, a actividade da fosfatase é 
extremamente baixa, levando a uma hiper-activação da via PI3K/Akt. 
Objectivos: Tendo em conta a importância que tanto factores do microambiente como 
alterações intrínsecas à célula têm na progressão tumoral através da regulação da via 
PI3K/Akt, pretendeu-se cumprir dois objectivos complementares nesta tese: estabelecer a 
importância relativa que GSK3β e FOXO3a têm aquando da estimulação de células de LLA-
T por IL-7; e definir o potencial terapêutico que a inibição conjunta de Notch e CK2 têm 
sobre a regulação do supressor tumoral PTEN em LLA-T. No primeiro objectivo, tentou-se 
perceber se a inactivação de GSK3β e FOXO3a é necessária para o completo efeito da IL-7. 
Para tal, subclonou-se mutantes constitutivamente activos (GSK3β.S9A e FOXO3a.A3) no 
vector lentiviral #304 e procedeu-se à transdução de células HPB-ALL e TAIL7. Foram feitas 
análises de sobrevivência e activação (por citometria de fluxo), proliferação (através da 
avaliação da incorporação de 3H-timidina) e estudos moleculares de expressão proteica (por 
Western Blot). No segundo objectivo, foram usadas linhas celulares PTEN+ (HPB-ALL, 
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TALL-1 e TAIL7) e procedeu-se à incubação das células com inibidores da γ-secretase 
(DAPT), para impedir activação de Notch, e inibidores de CK2 (DRB ou TBB), quer de forma 
isolada, quer de forma conjunta. Foram feitos estudos de activação celular (por citometria de 
fluxo), contagem do número total de células (usando o hemocitómetro, com exclusão de azul 
tripano) e proliferação (avaliação da incorporação de 3H-timidina). Em suma, como objectivo 
geral da tese pretendeu-se contribuir para a compreensão do papel e potencial terapêutico 
de proteínas envolvidas na regulação e função da via PI3K/Akt em LLA-T. Em última 
análise, as conclusões obtidas poderão eventualmente levar à definição de novos alvos 
terapêuticos e de novas estratégias de tratamento desta doença. 
Resultados: Relativamente à subclonagem de GSK3β.S9A, tento u-se inicialmente clonar 
no vector intermédio pBSKS- para depois se subclonar no vector lentiviral #304. Esta 
estratégia não funcionou devido ao elevado número de eventos de recombinação que 
ocorreram nas bactérias transformadas. Procedeu-se então à clonagem deste mutante por 
PCR. Desenharam-se e testaram-se primers específicos para o gene que continham locais 
para enzimas de restrição compatíveis com o vector #304. Usando o vector TOPO como 
vector intermédio, conseguiu-se então construir o vector final #304.GSK3β.S9A. Os 
resultados da sequenciação da clonagem revelaram existir uma delecção in frame de 39 
nucleótidos no gene. Por expressão transiente em células, verificou-se por Western Blot que 
a proteína mutante possuía um peso molecular superior ao esperado. Perante estes 
resultados aparentemente contraditório, reviram-se os dados obtidos e fez-se uma extensa 
pesquisa na literatura e PubMed. Descobriu-se então que se estava perante uma variante 
de splicing funcional do gene GSK3β, frequentemente expressa, que não inclui o exão 8b 
(daí os resultados da sequenciação apresentarem uma delecção), mas que inclui o exão 10 
(daí a proteína no Western Blot ter um peso superior à nativa das células). Portanto, a 
clonagem e expressão do gene estavam correctas e o mutante pode ser usado em 
experiências. 
Relativamente à clonagem de FOXO3a.A3 no #304, tendo este uma HA-tag, procedeu-se 
à encomenda de primers específicos para clonagem por PCR. Perante o insucesso em 
amplificar uma banda específica quando se pretendia incluir a HA-tag, decidiu-se então 
descartar a possibilidade de ter a HA-tag (não essencial para a execução do trabalho) e 
procedeu-se à clonagem de apenas FOXO3a.A3. A clonagem TA no vector TOPO não 
resultou, muito provavelmente devido, a este gene ser rico em GC,. Portanto, procurou-se 
um vector específico para clonagem GC. Após clonagem no vector intermédio e alguma 
optimização na ligação do mutante FOXO3a.A3 no #304, conseguiu-se finalmente construir 
o vector #304.FOXO3a.A3. A sequenciação do plasmídeo e expressão transiente em células 
293 confirmaram  que o mutante poderia ser usado em experiências. 
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Procedeu-se então à produção de lentivírus para transdução de da linha celular HPB-ALL. 
Infelizmente, a eficiência de transdução é baixa e, como tal, as análises funcionais 
subsequentes padecem de um efeito de diluição das células transduzidas nas não-
transduzidas (significativamente mais numerosas). As células foram então cultivadas com ou 
sem IL-7 e os resultados para o mutante FOXO3a.A3, embora não estatisticamente 
significativos, são promissores. FOXO3a constitutivamente activo em LLA-T parece baixar 
consistentemente a viabilidade, sendo que a presença de IL-7 não é suficiente para inverter 
esse efeito. Estes resultados preliminares sugerem que pelo menos a inactivação de 
FOXO3a.A3 parece ser necessária para que a IL-7 exerça completamente os seus efeitos 
anti-apoptóticos.  
No que respeita ao segundo objectivo, procedeu-se à incubação de linhas LLA-T positivas 
para PTEN com inibidores da γ-secretase e de CK2. Os resultados obtidos mostram uma 
diminuição do tamanho celular, viabilidade e proliferação das células quando incubadas com 
cada um dos inibidores. Mas este efeito é significativamente aumentado quando as células 
são incubadas com ambos os inibidores, demonstrando um efeito cooperativo entre os dois 
tipos de inibidores. Estes resultados apontam para uma possível nova estratégia 
terapêutica. Os dados aqui descritos estão incluídos num artigo original recentemente aceite 
para publicação (Silva, Jotta, Silveira, Ribeiro, et al. Regulation of PTEN by CK2 and Notch1 
in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and 
gamma-secretase inhibitors. Haematologica – aceite para publicção) 
Conclusões: Os objectivos do Capítulo 1 foram parcialmente atingidos, sugerindo que, 
pelo menos, a inactivação de FOXO3a é necessária à completa actividade da IL-7. No 
presente momento estão a pesquisar-se alternativas para contornar o problema da baixa 
infecciosidade das linhas celulares pelos lentivírus. Os objectivos do capítulo 2 foram 
completamente atingidos, levando a que se possa ponderar a inclusão do uso combinado de 
inibidores de Notch e CK2 no desenvolvimento de novas  estratégia terapêuticas para 
tratamento de doentes com LLA-T. 
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INTRODUCTION 
 
This thesis contains two major parts. In the first part, the role of two effectors of PI3K/Akt 
pathway is explored in the context of IL-7-mediated signaling. The second part investigates 
the therapeutic potential of targeting two known regulators of the PI3K/Akt pathway. To 
adequately   this Introduction includes a brief characterization of: 1) T-ALL and the 
importance of microenvironmental factors for tumor progression, highlighting the possible 
role of IL-7 in T-ALL establishment and progression; 2) the Jak/STAT pathway, which is 
important for normal T cell signal transduction and the signaling pathways that are the focus 
of this study (PI3K/Akt and Notch); 3) the PI3K/Akt effectors GSK3β and FOXO3a regulated 
in response to IL-7; 4) the PI3K/Akt negative regulator PTEN and its relation with Notch and 
CK2. Finally, the role of GSK3β, FOXO3a, PTEN and CK2 in normal cells and malignant 
cells is discussed. 
 
T cell Acute Lymphoblastic Leukemia 
Acute Lymphoblastic Leukemia is a type of leukemia characterized by an abnormal 
proliferation of immature cells of lymphoid lineage in the bone marrow or thymus that 
intravasate the peripheral blood and invade other organs. These cells are not 
immunologically functional and because of their increased proliferation rate they can impair 
normal hematopoiesis. ALL has a higher incidence in children until 5 years of age and is one 
of the most common cancers in this age-group. In young adults, the incidence of the disease 
decreases significantly but rises again in elderly [1, 17]. T-ALL is a subtype of ALL in which 
the immature cells are of the T lineage. The importance of studying T-ALL resides in part in 
the fact that the majority of the affected individuals are children and in the fact that, although 
the existing treatments are effective (more than 70% disease free survival at 5 years in the 
most successful protocols), a significant number of relapses still occur and have a dismal 
outcome. Moreover, severe long term complications often arise because of the elevated 
toxicity of the treatments [4]. There are many known alterations in the cellular genome that 
may lead to the development of ALLs, this are resultant from the exposure to several factors 
such as the inheritance of mutated alleles, overexposure to certain radiations and chemicals 
or late exposure to pathogens [1, 17]. However, genomic alterations are not the only events 
promoting the transformation of a normal cell into a cancer cell: the microenvironment has a 
fundamental role in the establishment of a tumor. Cancer cells are in constant cross-talk with 
the normal surrounding cells which are frequently subverted by the tumorigenic process and 
can, for instance, synthesize factors that promote tumor progression [4, 7].  
 
Interleukin 7 
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Normal hematopoiesis is stimulated by various cytokines, including, for example, SCF, 
CSFs and IL-7. Each one of these factors leads to the differentiation of certain hematopoietic 
lineages. IL-7 is mainly secreted by the stromal cells in the bone marrow and thymus, being 
essential to the proliferation of B and T cell precursors. Its receptor (IL-7R) is composed of 
two chains: IL-7Rα, specific for IL-7, and IL-2Rγ/γc, the gamma-common chain shared by 
receptors of the IL-2 cytokine family (IL-2, IL-4, IL-9, IL-15 and IL-21) [4, 18, 19].  
It has been demonstrated that IL-7 performs the function of growth and survival factor for 
normal cells as for T-ALL malignant cells, acting mainly through the PI3K/Akt pathway in the 
latter case. These functions are resultant of the increased expression of Bcl-2 and Cyclin D1 
proteins and decreased expression of p27Kip1, a CDK inhibitor [3, 4, 12]. Since malignant T-
ALL cells originate from normal T cell precursors, which rely on IL-7 for their development, 
they are easily exposed to the IL-7 present in the BM and thymic microenvironments. Normal 
T cell precursors stop dividing and differentiate in response to different stimuli, and are, at 
certain stages, highly prone to apoptosis, In contrast, T-ALL cells are blocked at a certain 
stage of differentiation, and thus may rely largely on the proliferative and survival signals of 
IL-7 without going through the apoptosis-prone process of T-cell differentiation. [4].  
 
Jak/STAT pathway  
Jak/STAT pathway is the canonical signaling cascada used by cytokines to transduce 
signals to target cells. Jaks are a family of tyrosine kinases with 4 known members: Jak1, 
Jak2, Jak3 and TYK2. Jaks are found associated with the intracellular part of the receptors. 
STAT proteins are a family of transcription factors with 7 members: STAT1, 2, 3, 4, 5a, 5b 
and 6. STATs are found in the cytoplasm in a monomeric and inactive form. After 
phosphorylation by Jaks they dimerize and become activated, being translocated to the 
nucleus, where they function as transcription factors and promote proliferation, differentiation 
and apoptosis [16, 19].  
In the case of IL-7 stimulation, after receptor binding, the dimerization of the receptor is 
promoted and the associated Jak proteins, Jak3 in γc and Jak1 in IL-7Rα, are 
interphosphorylated in the tyrosine residues of the Jak Homology 1 domain, becoming 
activated. After that, Jak 1 and 3 phosphorylate the receptor in target tyrosines, leading to 
the anchorage of STAT proteins, mainly STAT5a and 5b. In this way, STATs are recruited to 
the proximity of Jaks and are phosphorylated/activated, dimerizing and translocating to the 
nucleus. Once in the nucleus, STAT5 functions as a transcription factor for several genes 
that code for proteins involved in inducing survival, proliferation and cell cycle progression, 
such as Bcl-2, Bcl-XL, c-Myc, IL-2Rα e cyclin D1. Importantly, Jak substrates are not limited 
to STAT proteins, and include proteins which intervene in other signaling pathways, such as 
Ras/MAPK and PI3K/Akt [4, 16].  
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PI3K/Akt pathway 
PI3K/Akt signaling pathway is a master regulator of cellular homeostasis. The main 
elements of this pathway are PI3K, PTEN, PDK and Akt/PKB [11].  
The PI3K proteins belong to a family divided in 3 classes, being class I the most studied. 
This class is further divided in sub-classes Ia and Ib. The sub-class Ia contains the regulatory 
subunits of PI3K: p85α, p55α, p50α, p85β, p55γ, possessing two SH2 domains that allow the 
recognition of phosphorylated and between them the catalytic subunit (p110α, p110β ou 
p110δ) interaction domain. The sub-class Ib contains the catalytic and regulatory subunits 
p110γ and p101, respectively [15]. The various isoforms of PI3K are involved in the synthesis 
of phosphatidylinositols mono-, bi-, or triphosphate from the membrane phospholipids. The 
synthesis of PIP3 near the membrane recruits proteins that possess PH domains, such as 
PDK and Akt, allowing the activation of Akt. The antagonist of PIP3 synthesis is the 
phosphatase PTEN, converting PIP3 into PIP2, thus inactivating the PI3K/Akt pathway [10].  
When inactive, the serine/threonine kinase PDK1 locates in the cytosol, whereas when 
actiave it is found near the plasma membrane. This kinase is responsible for the 
phosphorylation of one threonine (T308) in the kinase domain of Akt, while PDK2 is 
responsible for the phosphorylation of one serine (S473) in C-terminal domain of Akt. The 
identity of PDK2 is still a matter of debate, although the protein complex mTORC2 is likely to 
constitute the PDK2 activity in most cells [4, 15].  
Akt is a serine/threonine kinase and the effector of the PI3K/Akt pathway. Three isoforms of 
this kinase are known: Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ. This enzyme has a great 
diversity of targets and phosphorylation by this kinase can either activate or repress the 
activity of the substrates. For example, Akt-mediated phoshorylation leads to inactivation of 
BAD, Caspase 9, Forkhead family members and GSK3β, while promoting the activation of 
IKK, Mdm2, and CREB. In this way, Akt influences many features that control the cell 
behavior, namely it promotes proliferation, inhibition of apoptosis and control of the 
metabolism [5, 8, 11, 15]. Summarizing, the activation of a receptor by its ligand or the cross-
talk with another signaling pathway triggers the activation of PI3K, leading to the synthesis of 
PIP3 which favors the activity of PDKs directing the phosphorylation and activation of Akt. 
Upon activation, Akt will interfere with the activity of many proteins tipping the balance 
towards survival and proliferation. Interestingly, it has been shown that activation of this 
pathway is essential for the viability and cell cycle progression of T-ALL cells mediated by IL-
7 in vitro, leading to the postulation that IL-7 may have a role in the establishment or 
maintenance of T-ALL [3, 4].  
The tumor suppressor PTEN is a lipid phosphatase that acts as the antagonist of PI3K, and 
is the most important downregulator of the PI3K/Akt pathway. The PTEN gene is frequently 
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silenced, mutated or deleted in different types of cancers, includin glioblastoma, melanoma, 
prostate and endometrium cancers, amongst many others. Mice heterozygous for the PTEN 
gene (PTEN+/-) have increased manifestation of several cancers, including leukemias and 
lymphomas. In T-ALL, low levels of PTEN protein activity are frequent, resultant mainly form 
transcriptional down regulation or gene silencing and posttranslational modification. 
Transcriptional downregulation is discussed in the Notch pathway section below, and the 
posttranslational modification is discussed in the CK2 section. [29, 30]. 
 
Notch pathway 
Notch signaling pathway is a highly conserved pathway across the animal kingdom. Notch 
is implicated in stem cell fate determination and patterning events, controlling differentiation, 
proliferation and apoptosis. Correct Notch signaling is fundamental during embryogenesis 
[25].  
In mammals, four Notch surface receptors (Notch1-4) and five ligands (Delta-like 1, 3 and 
4, and Jagged 1 and 2) are described. Upon ligand-receptor binding, Notch receptor 
undergoes two proteolytic cleavages: first by TACE, releasing the ligand-bound part of 
Notch, and second by the γ-secretase complex, releasing the Notch Intracellular Domain 
(NICD), the active signal-transducing fragment. NICD is then imported to the nucleus 
promoting the transcription of direct and indirect target genes: Hes1, Hey, c-Myc, Cyclin D1, 
implicated in augmented survival and proliferation [21].  
Alterations in Notch signaling mechanisms have several implications due to abnormal 
signaling patterns. In cancer, increased Notch signaling has been correlated with the 
development of melanoma, breast cancer, myeloma and leukemia. [21, 25]. In T-ALL, 
Notch1 activating mutations have been described for more than 50% of diagnostic T-ALL 
cases leading to an increased γ-secretase complex activity and production of NICD. Also, 
increased Notch activity has been associated with a decrease in PTEN transcription leading 
to an upregulation of the PI3K/Akt pathway. This effect appears to be exerted by 
upregulation of HES1, a direct transcriptional target of Notch and a transcriptional repressor 
of PTEN [20, 23].  
 
FOXO3a  
The protein Forkhead box O3a (FOXO3a) belongs to an extense family of transcription 
factors with the Forkhead Box domain organized in groups ranging from FOXA to FOXS. The 
FOXOs have a wide distribution in all tissues of the body and have been implicated in 
several processes like: aging, cancer, diabetes, neurodegeneration and infertility [13]. 
FOXO3a directly induces the expression of Gadd45, TRAIL, Bim, Noxa, FasL, p27Kip1 and 
other promoters of apoptosis and inhibitors of the cell cycle [9, 12, 13]. Phosphorylation of 
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FOXO3a by Akt leads to FOXO3a inactivation due to the export of the transcription factor 
from the nucleus and subsequent retention in the cytoplasm [9, 13]. Another antagonist of 
FOXO3a is IKK (also activated by Akt) which phosphorylates and marks it for destruction by 
the proteasome [9]. After stimulation by IL-7, PI3K/Akt pathway is activated and 
consequently FOXO3a is phosphorylated/inactivated. In this thesis the mutant FOXO3a.A3 
will be used. This mutant has the three Akt serines substituted by non-phosphorylatable 
alanines, rendering it permanently active even in the presence of activated Akt.  
 
GSK3  
The enzyme Glycogen Synthase Kinase 3 (GSK3) is a serine/threonine kinase initially 
discovered as an enzyme capable of phosphorylating glycogen synthase, however today 
there are more than fifty known substrates. This kinase regulates several processes, namely 
cell structure, metabolism and apoptosis. Two isoforms of this enzyme exist: GSK3α and 
GSK3β. GSK3β activates pro-apoptotic proteins – BAX, Bim, p53 – and inactivates anti-
apoptotic proteins and promoters of the cell cycle – Mcl-1, CREB, Cyclin D1, c-Myc [14]. 
Upon activation of the PI3K/Akt pathway, GSK3β is phosphorylated and thereby inactivated 
by Akt [6, 14]. In this thesis the mutant GSK3β.S9A will be used. This mutant has a 
substitution of serine to alanine, making it permanently active even in the presence of 
activated Akt.  
 
CK2 
Protein kinase CK2 is a ubiquitous serine/threonine kinase highly conserved in eukaryotes. 
It is composed of two regulatory α subunits, for which two isoforms exist (α and α’) and two 
catalytic β subunits. These isoforms have the same catalytic activity, although they seem to 
have specialized functions, since they are differently modified by other proteins (e.g. p34cdc2), 
and have different binding capacities (e.g. towards CKIP1) [31]. 
CK2 has a broad range of substrates either in the nucleus or cytoplasm. These substrates 
often include proteins involved in the proliferation and survival of the cell. The failure to 
produce CK2 knock-out mice, shows that this kinase is essential for survival. Given the 
extensive amount of CK2 substrates and interactions, its regulation appears to be highly 
complex and poorly understood [27]. 
A great number of studies have implicated an increased activity of CK2 in malignant 
transformation, and tumor aggressiveness. Increased expression of CK2 is found in kidney, 
prostate, breast, lung cancers as well as in leukemias. CK2 was shown to phosphorylate 
tumor suppressors in key residues, promoting their faster degradation (PML protein) or their 
stabilization in its inactive form (PTEN protein). Oncogenes are also targets of CK2, but in 
their case the phosphorylation by CK2 leads to an altered and increased activity (e.g. c-Myc, 
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NK-κB or Akt). Also, CK2 can modulate the apoptotic machinery. Inhibition of CK2 in prostate 
cancer cells, leads to a decrease in the anti-apoptotic Bcl-2 and Bcl-xL proteins, and an 
increase in the pro-apoptotic Bax protein [29, 31]. 
In T-ALL, CK2 was shown to be frequently overexpressed and to promote the inactivation 
and stabilization of the tumor suppressor PTEN, leading to a state in which the cells had high 
levels of inactive PTEN and consequent hyperactivation of the PI3K/Akt pathway [29]. 
 
Figure 1 shows a summarized scheme of the signaling effects of IL-7, Notch and CK2 upon 
PI3K/Akt pathway, based on what is currently known regarding  T-ALL cells. The first part of 
this project focused on the attempt to assess the role of FOXO3a and GSK3β in IL7-
mediated signaling towards a therapeutic approach. The second part of the thesis focused in 
testing whether combined use of CK2- and γ-secretase (Notch) inhibitors may have 
therapeutic potential in T-ALL. 
 
 
 
 
 
 
 
 
 
Figure 1 – Schematic representation of the effects on the 
PI3K/Akt pathway of the external stimulus IL-7 and the 
cell-intrinsic molecules Notch and CK2 in T-ALL cells. 
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OBJECTIVES 
 
The major aim of this thesis is to the understand the role and therapeutic potential of 
proteins involved in the regulation and functional activity of the PI3K/Akt signaling pathway in 
T-ALL. The conclusions obtained may contribute to the rational definition of new therapeutic 
targets and development of novel treatment strategies. 
Chapter 1 detailed objectives: 
The main objective of this part of the thesis was to establish the relative importance of two 
proteins, GSK3β and FOXO3a, regulated by the PI3K/Akt pathway, upon IL-7 stimulation, in 
the proliferation and viability of T-ALL cells. In an initial approach, studies were made to 
investigate if the inactivation of these proteins is necessary for the full functionality of IL-7.  
To accomplish the task, GSK3β.S9A and FOXO3a.A3 constitutively active mutants will be 
subcloned in the #304 lentiviral vector, lentiviruses will be produced. To obtain robust 
conclusions, transductions of either an IL-7 responsive cell line (HPB-ALL) and IL-7 
dependent cell line (TAIL7) should be made. Several techniques were used to analyze the 
functional effects of the genes: flow cytometry, incorporation of 3H-TdR and Western Blot.  
Chapter 2 detailed objectives: 
The main objective of this part of the thesis was to establish the therapeutical potential of 
combined Notch inhibition by using DAPT as a γ-secretase inhibitor, and CK2 inhibition by 
using DRB or TBB as CK2 inhibitors, in the regulation of the tumor suppressor PTEN. The 
following PTEN positive cell lines were used: HPB-ALL, TALL-1 and TAIL7. 
To accomplish the task, the cell lines were cultured with DAPT, DRB or TBB, or both DAPT 
and DRB/TBB. To analyze the effects of the inhibitors flow cytometry, cell counts (using a 
hemocytometer and trypan blue exclusion) and proliferation by 3H-TdR incorporation were 
used. 
The role and therapeutic potential of regulators and effectors of PI3K/Akt pathway in T-cell leukemia 
Daniel Filipe Silva Ribeiro   8 
MATERIALS AND METHODS: 
 
To simplify the reading, brands and models of equipment and reagents will be indicated 
only once. 
 
1 – Culture of bacteria cells and DNA cloning:  
The manipulation of bacteria cells, which required sterile conditions, was performed under 
the flame. The culture in Petri dishes was incubated at 37ºC in an incubator. The suspension 
culture was made at 37ºC in an orbital mixer Agitorb 200 (Aralab). The measurements of 
DNA concentration were performed in a spectrophotometer NanoDrop 2000c (Thermo Fisher 
Scientific). 
Digestion with restriction enzymes: For a maximum volume of 20μL, the following 
reagents we added by this order: needed volume of H2O, 1-10μg of DNA, 2μL of adequate 
enzyme Buffer 10x (Promega), 2μL BSA 10x (Promega), 1-2μL enzyme(s) (Promega), the 
reaction was incubated at 37ºC, 1h to 1h30min. 
Klenow Fragment reaction: after purification od the DNA with the Wizard® SV Gel and 
PCR Clean-Up System kit (Promega), reagents were added by this order: for 20uL of 
volume: needed H2O, needed amount of DNA, 2μL of Klenow Buffer 10x (Fermentas), 2μL of 
BSA 10x, 0.5uL of Klenow (Fermentas), 0.5μL of dNTPs at 10mM. Incubate at 25ºC, 15min, 
followed by heat-inactivation for 20min at 75ºC and then cooled in ice. 
Agarose gel electrophoresis in TAE buffer: An agarose gel was prepared using a 1% 
w/v agarose proportion in TAE buffer 1x supplemented with 0.5μg/mL of Ethidium Bromide. 
Orange G sample Buffer 5x was added to the samples to a final concentration of 1x. The 
molecular weight marker 1kb Gene Ruler DNA Ladder (Fermentas) was used (Figure 2). The 
electrophoresis ran at 86V during 45-60min according to the size of the fragments to resolve. 
The gels were visualized under a UV light (285nm) transillumintor (UVP) and photographed 
with a Kodak Edas 290 camera (Kodak). When the fragment was one of 
interest, we proceeded to the excision and purification of the DNA from 
the gel with the Wizard® SV Gel and PCR Clean-Up System kit. 
 
 
 
 
 
Figure 2 – Range and resolution of the DNA molecular weight marker 1Kb Gene Ruler 
DNA Ladder, by standard manufacturer’s conditions. From the manufacturer’s website. 
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Cloning in commercial TOPO (Invitrogen) and pGC.Blue (Lucigen): the cloning in both 
these commercial vectors was made according to the manufacturer’s instructions. The E. coli 
strain provided with the TOPO vector is DH5α and the one provided with the pGC.Blue kit is 
10G. 
Cloning in non-commercial vectors: The cloning was performed for a maximum of 200ng 
of DNA and a maximum volume of 15μL of the reaction, in the proportion of DNA vector to 
DNA insert: 100ng vector  vector size (Kb) = Xng insert  insert size. To increase the odds 
of ligation X was multiplied by 3. By this order the following, reagents were added: needed 
volume of H2O, needed amount of vector DNA and insert DNA, 1.5μL T4 DNA Ligase Buffer 
10x (Fermentas), 1μL T4 DNA Ligase (Fermentas). The mix was incubated at 15ºC in a 
termocycler MyCycler (Bio Rad), over-night, followed by transformation of competent 
bacteria. 
Chemical Transformation of competent E. coli: LB medium (1L): 10g Tryptone, 5g Yeast 
Extract, 10g NaCl in 1L ddH2O was autoclaved. LB Agar (1L): 15g Agar (IDG) in 1L LB. SOB 
medium (1L): 20g Tryptone (Becton-Dickinson), 5.0g yeast extract (Becton-Dickinson), 0.5g 
NaCl (Sigma), added H2O until 1L. After autoclave, added sterile 10mL of MgCl2 1M (Sigma) 
and 10mL of MgSO4 1M (Sigma). SOC Medium (100mL): 1mL glucose 2M (Sigma) sterile 
and 99mL SOB medium. 
For the amplification of #304 based vectors the E. coli strain JM109 (Stratagene) was used. 
1-5μL of DNA was used to transform ice thawed competent bacteria, followed by 30min 
incubation on ice. Then a thermal shock of 45seg at 42ºC followed by 2min in ice was done. 
Next, 900μL of SOC medium was added and bacteria were incubated for 1h at 37º C in 
orbital agitation 250rpm. Bacteria were then centrifuged at 13000rpm for 1min and the pellet 
was ressuspended in LB and plated in LB-Agar dishes pre-warmed at 37ºC. The blue/white 
screening was performed by spreading in the surface of the Petri dishes 40μL of X-Gal 
(Promega) 50mg/mL. The antibiotic screening was made by adding 100μg/mL ampicillin to 
LB-Agar or kanamycin 30μg/mL to LB-Agar. 
PCR:  
Primers for GSK3.S9A:  
GSK3 Fwd (SphI) – 5’ CATGCATGC
GSK3 Ver (SalI) – 5’ GC
AAGATGTCAGGGCGGCCCAGAA 3’.  
GTCGAC
Primers for FOXO3a.A3:  
TAATCAGGTGGAGTTGGAAGCTG 3’. 
HA Fwd (SphI) – 5’ CATGCATGC
HA New (SphI) – 5’ CAT
TGGATGTAC CCA TAC GAT GTT CC 3’.  
GCATGC
FOXO Fwd (SphI) – 5’ CAT
TGGATGTAC CCA TAC GAC GTC CCA GA 3’.  
GCATGC
FOXO Rev (SalI) – 5’ GC
TGGATGGCAGAGGCACCG 3’.  
GTCGAC
Restriction enzyme recognition site is underlines in the primers. 
TAATCAGCCTGGCACCCAGCT 3’. 
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For the PCR reaction were added in the following order: needed volume of H2O, Pfu Buffer 
10x (Promega) and DMSO (Sigma) to a final concentration of 10% (v/v) each, followed by 
addition of each Primer (Invitrogen) to a final concentration of 100nM, between 100-500ng of 
DNA and 2Units/μL of reaction of Pfu DNA Polymerase (Promega) . The PCR program used 
was the following, in a termocycler MyCycler: 94ºC – 5min (denaturing), [94ºC – 30sec 
(denaturing), variable annealing temperature for 1min and 30sec, 72ºC for variable extension 
time]x32, 72ºC – 7min (final extension), 4ºC – 5min. 
Bacteria culture for miniprep: Glycerol Stocks were performed in the following way: a 
300μL of an over-night culture of bacteria was mixed with 300μL of LB medium 
supplemented with 30% (v/v) glycerol (Sigma) and supplemented with the respective 
selection antibiotic.  
2mL of LB medium supplemented with the respective selection antibiotic was poured in a 
Falcon tube (Orange Scientific). A bacterial colony or a part of a glycerol stock was picked to 
the Falcon tube. The Falcon tube was incubated in an orbital mixer, 250rpm, over-night. 
Bacteria was precipitated at 13000rpm, 5min, followed by supernatant discard and stored at -
20ºC.   
Small scale DNA extraction by the 1,2,3 process for: Solution 1: 50mM Glucose, 25mM 
Tris-HCl pH=8, 10mM EDTA (Sigma) and 100μg/ml Rnase (Promega). Stored at 4º C. 
Solution 2: 0,2 N NaOH and 1% SDS (Sigma) w/v. Stored at room temperature. Solution 3: 
11,5% v/v Glacial Acetic Acid and 3M KOAc. Stored at 4ºC. 
From a previously prepared miniprep, the pellet was ressuspended in 250μL of Solution 1 
by vortexing. Then 250μL of Solution 2 was added, inverted and rested for 3min at room 
temperature. Next, added 350μL of Solution 3, inverted and centrifuged at 13000rpm, 10min. 
The supernatant was transferred to a new microtube and 500μL of isopropanol were added 
and the tube inverted, followed by a centrifugation at 13000rpm, 30min, 4ºC. Next, 500uL of  
-20ºC stored EtOH was added to the pellet, followed by centrifugation at 13000rpm, 10min at 
room temperature. Then, all EtOH was removed and the DNA pellet was air dryed. The DNA 
was eluted in 30μL of ddH2O. 
Bacteria culture for maxiprep: A previous miniprep culture was added to 150mL of LB 
supplemented with the respective selection antibiotics and incubated in an orbital mixer, 
200rpm, over-night, followed by centrifugation at 4000rpm, 4ºC in Eppendorf 5810R 
centrifuge. The pellet was stored at -20ºC. 
Maxiprep DNA extraction: the extraction was made using the Genopure Plasmid Maxi Kit 
(Roche) following manufacturer’s instructions. 
Sequentiation analysis: the analysis was made with the freeware software BioEdit. 
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2 – Culture of human cells, production and viral transduction, experimental and 
analytical techniques:  
The manipulation of cells, which required sterile conditions was made in a vertical laminar 
flow chamber Hera safe (Heraeus) and its culture inside a Hera cell (Heraeus) CO2 incubator 
at 37ºC, 5% CO2. Washing/centrifugation of cells, in Falcon tubes, was performed in a 
Sorvall RT7 plus centrifuge at 10ºC, 1700rpm, 7min. Washing/centrifugation of cells in 
microtubes was performed in a 4ºC Biofuge fresco (Heraeus) centrifuge at 4ºC, 3200rpm, 
7min. Cell counts were performed by Trypan Blue (Sigma-.Aldrich) exclusion in a 0.08% 
solution. Suspension cells were cultured in RPMI (Invitogen) with 5% or 10% FBS, 
designated R5 or R10, respectively. Adherent cells were cultured in DMEM (Invitrogen) with 
10% FBS, designated D10. All culture mediums were supplemented with 
Penicillin/Streptomycin 1x (Invitrogen). 
293T adherent cell culture: Thawing: a vial was thawed into 37ºC pre-warmed D10. Cells 
were seeded in a T75 flask (Nunc). The medium was changed in the following day. Culture: 
enough volume of pre-warmed D10 was used to cover the bottom of the flask. Cell passage: 
in this step, pre-warmed PBS and D10 were used. The flask bottom was washed and trypsin-
EDTA 1x 0.05% (Invitrogen) was added and incubated at 37ºC until the cells detached. 
Trypsin was then inactivated by adding D10 medium. Cells were then filtered through a 
0.70μm cell strainer (BD Falcon™), followed by centrifugation. Cells were then counted and 
seeded again.  
HPB-ALL and TALL1 cell culture: Thawing: a vial was thawed into pre-warmed R10. 
Cells were seeded in a T25 flask. In the following day the cells were washed and counted. 
When the proportion of dead cells was higher than 20% of total cells, Lympholyte 
(Cederlane) was used, according to the manufacturer’s instructions to separate live from 
dead cells. Culture: every three days the cells were counted and diluted to a concentration of 
1*106cells/mL for HPB-ALL or 0.5*106cells/mL for TALL1 in R10.  
TAIL7 cell culture: Thawing: a vial was thawed into pre-warmed R5. Cells were washed, 
counted and Lympholyte was used to purify the live cells. Culture: every 3 days the cells 
were counted and diluted at 2*106cells/mL in R5 supplemented with 10ng/mL of IL-7, in 24-
well plates (TPP). Once a week, live cells were purified by using Lympholyte. 
Cell freezing (per cryovial): Cells were frozen in a suspension of 1.8mL of FBS with 10% 
(v/v) DMSO. Cryovials of 1.8mL (Nunc) were pre-cooled at 4ºC. After washing cells were 
ressuspended in 900μL of FBS and stored at 4ºC for 1h. A solution of 900μL FBS with 20% 
(v/v) DMSO was prepared and refrigerated at 4ºC and then was added dropwise to the cell 
suspension, stirred gently. Cryovials were stored at –80ºC in a cryobox. The following day 
the cryovials were moved to liquid N2. 
The role and therapeutic potential of regulators and effectors of PI3K/Akt pathway in T-cell leukemia 
Daniel Filipe Silva Ribeiro   12 
Mammalian cell lysis for Western Blot: Lysis buffer: 50mM Tris-Base, 150mM NaCl, 
5mM EDTA, 1mM NaOVa (Sigma), 10mM NaF, 10mM Sodium Pyrophosphate (Sigma), 1% 
NP-40, 10μg/ml Aprotinin (Sigma), 1μg/ml Pepstatin (Sigma), 10μg/ml Leupeptin (Sigma). 
Stored at 4ºC. 
A minimum of 5*106 cells was pelleted, the supernatant discarded, 1μL of AEBSF 100mM 
(Sigma) protease inhibitor was added and the pellet was ressuspend in a 70-100μL of Lysis 
Buffer, according to the number of cells and pellet size. A centrifugation at 13000rpm, 10min, 
4ºC was performed and the supernatant (protein extract) was transferred to a new microtube 
and Stored at -20ºC. 
Protein quantification: a sample of the protein extract was added into a 20% solution of 
Bradford Reagent (Bio Rad) performing a 1:500 (v/v) dilution of sample. The quantification 
was assessed in a GeneQuantpro (Amersham Biosciences) spectrophotometer at 595nm 
wavelength. 
SDS-PAGE electrophoresis: 12% acrylamide resolving gel at (per gel): 5mL Resolving 
buffer (375mM Tris base, pH=8.8), 3.85mL of ddH2O, 6mL Acrylamide (National 
Diagnostics), 33.5μL APS 20%, 150μL SDS 10%, 15μL TMED (Bio Rad). Stacking gel (per 
gel): 1.3mL Stacking buffer (125mM Tris Base, pH=6.8), 5mL ddH2O, 0.75mL Acrylamide, 
22.5μL APS 20%, 13μL TEMED. Running buffer (5L, 1x): 30.25g Tris base, 144g glycine 
(Sigma), 5g SDS, H2O to 5L. 
Lysis Buffer was added to the volume of protein extract correspondent to 50μg of protein. to 
to uniformize the volume of the samples. 3x Sample Buffer (Bio Rad) was added to the 
samples for a final concentration of 1x and incubated at 90ºC,10min, for denaturation. After 
cooling on ice, the samples were loaded in the gel. To equilibrate the gel the same volume of 
Sample Buffer was added to empty wells. The gel ran in Running Buffer, at 90V during the 
Stacking half and at 100V during the Resolving half.  
Western Blot transference, probing, development and stripping: Transfer buffer basic 
(8L, 1x): 30g Tris base, 144g glycine, filled with H2O until 8L. Transfer buffer for use (1L): 
800mL Transfer Buffer basic, 200mL methanol. TBS (5L, 10x): 440g NaCl, 60g Tris base, 
pH=7.6, filled with H2O to 5L. TBSt 1% (1L): 1L TBS 1x, 1000μL Tween 20. Blocking solution 
for Western Blot: TBSt added with 3% (w/v) of skimmed milk. 
Transference: the polyacrylamide gel was assembled next to a nitrocellulose membrane, in 
Transfer Buffer, so that when exposed to electrical current (100V, 1h30min) the proteins 
would pass from the gel to the membrane. The Western Blot membranes were always 
washed in TBSt with permanent agitation. Primary antibody probing: depending on the 
antibody, different dilutions were done in TBSt supplemented with 1:100 (v/v) of NaN3 2% 
(w/v) solution, then incubated over-night at 4ºC with slow agitation, followed by three washes 
15+5+5min. Secondary antibody probing: HRP conjugated antibody, directed against the 
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species of the primary antibody, was diluted 1:5000 (v/v) in TBSt 3% milk, then incubated at 
room temperature, 1h with slow agitation. Three washes of 15+5+5min were made. 
Development: the membranes were incubated in a mix of 500μL of two Pierce ECL Western 
Blotting Substrate (Thermo Scientific) solutions and after 3min were developed, by . 
Stripping: the membranes were incubated in Stripping Buffer (15 mM Tris base, 100 mM 2-β-
Mercaptoethanol (Sigma), pH=6.7) and supplemented with 1:1000 (v/v) dilution of 2-β-
Mercaptoethanol, followed by Incubation for 45min, at 56ºC with agitation. 
Lentivirus production: 293T cells passed frequently (2-3x a week) and of early passage 
(max. P20) were used. All supernatants were collected and filtered by 0.45μm filters, frozen 
in liquid N2 and stored at -80ºC. The DMEM-10 and PBS were always used pre-warmed at 
37ºC. Day 1: Petri plates were covered with 3mL PDL 10µg/mL. for 20min. Per plate, 2*106 
293T were seeded in 10mL of D10. Day 2: 1h before transfection  the medium was changed 
to 10mL of D10 supplemented with 25µM of chloroquine. Transfection per plate: 5.1μg #304 
vector, 3.1μg pMDLg, 1.4μg pRSV.Rev, 2.0μg pMD2.VSVg were mixed  in a 450μL solution 
of CaCl2 0.25M . The DNA mix was added dropwise, to 450μL of HBSP 2x (1.5mM Na2HPO4 
(Sigma),10mM KCl (Sigma), 280mM NaCl, 12mM glucose, 50mM HEPES, adjusted to 
pH=6.95). After 5min rest at room temperature, 900μL of the DNA precipitate was added 
dropwise to each plate. Day 3: in the morning the dishes were washed with PBS. From this 
point on, all fluids and tips were discarded to a Virkon solution (Antec International). To each 
plate, 6mL of D10 supplemented with 20mM HEPES (Sigma) and 10mM Sodium Butyrate 
was added. 8h after the 1st supernatant and a titration aliquot were collected and D10 + 
HEPES medium was added. Day 4: in the morning the 2nd supernatant and a titration aliquot 
were collected and D10 + HEPES medium was added. Day 5: the 3rd viral aliquot and the 
titration aliquot were collected. The plated were washed and the cells ressuspended in PBS 
for acquisition in a Flow Cytometer to determine the transfection efficiency (GFP+ cells).  
TAIL7 lentiviral transduction: The infection was done using a MOI between 10 to 25 in 
24-well plates. Day 1 The viruses were concentrated in an Amicon Column (Millipore) 
following the manufacturers’ instructions. Half the volume of concentrated supernatant was 
frozen in N2 liquid for the next day. The plates were covered with 250 μL of Retronectin 
(Takara) at 20μg/mL and left to rest 2h at room temperature. The wells were washed with 
PBS and 500μL of TAIL7 cells in R5 supplemented with 40ng/mL of IL7 were seeded 
together with 500μL of viral supernatant, per well. Day 2: 700μL of medium were carefully 
removed from the wells and 500μL of R5 supplemented with 40ng/mL of IL7 was mixed with 
500μL of viral supernatant, per well. Day 3: The transduction efficiency was assessed in 
FACS (GFP+ cells) and the cells readied for sorting. 
HPB-ALL lentiviral transduction: The infection was done using a MOI=2.5 in 24-well 
plates (TPP). Per well, a maximum of 500μL of concentrated viral supernatant and 500μL of 
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cell containing medium were mixed and supplemented with 8μg/mL of polybrene (Sigma). 
The cells were cultured with viruses for 48h. The viruses were washed out and HPB-ALL 
were cultured for 24h in R10, for recovery. The transduction efficiency was analyzed in a 
Flow Cytometer (GFP+ cells). 
Flow Cytometry staining: All sample acquisitions were performed in a Flow Cytometer BD 
FACSCalibur™. The cell sorting was performed in a BD FACSAria™ cell sorter. Flow 
cytometry data analysis was made in a Mac with the FlowJo™ software. Antibodies: cells 
were washed with PBS (maximum of 106 cells for described volumes). Supernatant was 
discarded and cells ressuspended in 100μL of PBS. The antibody was added and incubated 
in the dark for 30min at 4ºC. Excess antibody was washed by adding 1000μL de PBS, 
followed by centrifugation. The cells were ressuspended in 200uL of PBS and acquired. 
TMRE: cells were collected and incubated in RPMI-1 with 100nM TMRE (Invitrogen) in the 
dark at 37ºC for 15min in a final volume of 200μL and then acquired. AnnV/7AAD: cells were 
washed/centrifuged in PBS, and the pellet was ressuspended in 100μL of AnnV Binding 
Buffer 1x (BD). 1μL of AnnV-APC (BD) and 2μL 7AAD (BD) were added per sample. The 
samples were incubated in the dark at room temperature, 15min. Before acquisition 100μL of 
AnnV Binding Buffer 1x was added and samples were acquired. 
HPB-ALL survival experiments: after transduction and recovery, the cells were washed 
and incubated in 96-well plates with RPMI-1% FBS and with or without IL-7, in triplicates. 
After 48h and 72h post-incubation the cells were harvested and the adequate flow cytometry 
stainings were performed: TMRE, AnnexinV-APC and 7AAD. When analyzing the data, the 
gating strategy was the following: gated on the whole cell population to exclude debris; 
subgated on the live cells; subgated on the GFP+ cells; then either subgated to distinguish 
TMRE-/+ cells or subgated to distinguish AnnV-7AAD-/AnnV+7AAD-/AnnV+7AAD+. 
Cell Sorting: The cell sorting was performed in a BD FACSAria™ Cell Sorter. Sample 
preparation: the cells were passed through a 0.70μm cell strainer and washed with 
PBS.Cells were ressuspended PBS- EDTA 5mM supplemented with twice the concentration 
of Penicillin/Streptomycin used in the culture medium and Gentamicin at 100μg/mL. The cells 
were sorted to R20 medium containing the same concentration of antibiotics as in the pre-
sort medium. The sorted cells were the GFP+ cells. 
Inhibitors protocol: cells were cultured in 24- or 96-well plates, in conditions already 
described. The medium was supplemented with DAPT, DRB, TBB or DMSO (vehicle). 
Inhibitors were stocked at 25mM. Cell size was analyzed by Flow Cytometry, cell counts by 
trypan blue exclusion in a hemocytometer and proliferation by 3H-TdR incorporation. 
Minimum tested dose of each inhibitor (1, 5 or 10M DAPT; 12.5 or 25M DRB/TBB) that 
originated at least a 10% inhibitory effect was identified for each cell line, for each functional 
assay, and used in combination for the assessment of cooperative effects. For primary T-ALL 
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cells, the TBB dose had been previously determined (4) and DAPT was tested at a single, 
high concentration (5M). 
3H-TdR protocol: a stock of 250μL of tritiated thymidine in 6mL of RPMI was prepared. 
25μL of stock solution was added per well of a 96-well plate to the cells, followed by a 16h 
culture with the tritiated thymidine. Plates were frozen and then Analyzed in a β liquid 
scintillation counter.  
Statistical analysis: Graphics and statistical analysis were performed in the software 
GraphPad Prism 5. 
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RESULTS AND DISCUSSION – CHAPTER 1: 
Constructing Lentiviral Vectors to Express Effector Genes Involved in PI3K/Akt 
Pathway  
Assessing Their Role in IL7 Mediated Signaling of T-ALL
 
In this thesis lentiviruses were chosen, over other kinds of viruses, to transduce HPB-ALL 
and TAIL7 cells, because of their reported ability to transduce non-dividing or slow dividing 
cells such as TAIL7. The #304 lentiviral vector (kindly provided by Prof. Luigi Naldini via Prof. 
João Gonçalves) allows, together with other vectors of the packaging system (pMDLg, 
pRSV.REV, pMD2.VSVg), the construction of replication-defective lentiviruses. The #304 
plasmid has another interesting feature, a bidirectional promoter system (fig S5). This system 
has the reporter gene GFP transcribed under the minhCMV promoter in one direction and 
the gene of interest transcribed under the hPGK promoter in the opposite direction, this 
allows a more stable and stronger expression of the gene of interest. 
 
Cloning GSK3β.S9A into the #304 vector and assessing its expression: 
The initial plan was to subclone the GSK3β.S9A gene from the pSG5.GSK3β.S9A (fig. S1) 
vector to the #304.Ø vector. Due to the lack of adequate restriction sites present in both 
pSG5 and #304 vectors and because it is known from previous experiments that it is very 
hard to perform blunt end ligations in the #304 vector, the subcloning strategy passed by 
cloning the fragment of interest in a intermediate vector, pBSKS- (fig. S2), which contains 
identical restriction sites to those found in the #304 vector. The steps undertaken were the 
following: first, the pSG5.GSK3β.S9A vector was digested with BglII, with subsequent 
polymerization with the Klenow Fragment in order to create a blunt extremity followed by the 
digestion with EcoRI. In parallel, the pBSKS- vector was digested with HindIII, and a 
subsequent polymerization with the Klenow Fragment was made to create a blunt extremity, 
followed by a final digestion with EcoRI. Next, the fragment generated from the digestion of 
pSG5.GSK3β.S9A was ligated into the digested pBSKS-. After cloning the GSK3β.S9A gene 
in the pBSKS- vector, a parallel digestion of this vector and the #304.Ø vector with PstI and 
SalI was done and the GSK3β.S9A gene containing PstI (5’)/SalI (3’) extremities were ligated 
in the digested #304.Ø vector, therefore constructing the #304.GSK3β.S9A. All the 
digestions were performed as described in Methods but with some alterations imposed by 
the enzyme BglII, which  was not heat-inactivated and had to be purified by the Wizard® SV 
Gel and PCR Clean-Up System kit, and by the use of the Klenow Fragment which was used 
in a reaction alone and then heat-inactivated.  
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Digestion of pSG5.GSK3β.S9A and pBSKS-: following the digestion of both vectors, all the 
products were loaded in a 1% agarose gel and an electrophoresis was performed. The 
results obtained are displayed in the Figure 3. 
 
 
 
Figure 3 – Parallel digestion of pSG5.GSK3β.S9A and pBSKS
-
 
vectors evidenced in a 1% agarose gel electrophoresis. Lane 1 
– Molecular weight marker. Lane 2 – pSG5.GSK3β.S9A after 
digestion with  BglII and EcoRI, with GSK3β.S9A marked within 
the red rectangle. Lane 3 – pBSKS
-
 after digeston with HindIII 
and EcoRI, with the linearized vector marked within the red 
rectangle. Lane 4 – uncut pSG5.GSK3β.S9A. Lane 5 – uncut 
pBSKS
-
. 
 
 
The pSG5.GSK3β.S9A plasmid had ~5.4Kb of size. After the digestion with both enzymes, 
two fragments were expected: one containing the GSK3β.S9A (~1.3Kb) and the remaining 
vector (~4.1Kb). Lane 2 of fig. 3 shows the expected fragments. The pBSKS- plasmid had 
~3.0Kb of size. Two fragments were expected after the digestion: one with 12bp of very fast 
migration that could not be detected in the gel, and another with ~3.0Kb of size. Lane 3 of fig. 
3 shows the linearized vector. Given the positive result obtained, the fragments marked 
within the red rectangle in fig. 3 (GSK3β.S9A and pBSKS-) were excised from the gel, 
purified, ligated and transformed in JM109 E. coli as described in the Methods. The 
transformed bacteria were grown and selected in Petri dishes prepared for colorimetric (lacZ 
based) and ampicillin selection. Using this strategy, the white colonies were supposed to be 
the positive transformants, because the ligation in the MCS of this vector disrupts the lacZ 
gene, thereby keeping the colonies white in the presence of X-Gal. In the next day, ten white 
colonies were grown for minipreps. After DNA extraction, a digestion of all the colonies plus 
the #304-Ø vector was performed with the enzymes PstI e SalI. The results obtained are 
shown in Figure 4.  
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Figure 4 – Digestion of DNA from the selected colonies transformed with the pBSKS-.GSK3β.S9A ligation 
evidenced in a 1% Agarose gel electrophoresis.  Lane 1 – Molecular weight marker. Lanes 2 to 10 – Selected 
colonies digested with PstI and SalI. Lane 11 – pBSKS- digested with PstI and SalI. Lane 12 - #304.Ø digested 
with PstI and SalI.
 
If no recombination had occurred, the digestion of the colonies should yield 2 fragments: a 
~3.0Kb fragment (pBSKS-) and a ~1.3 Kb fragment (GSK3β.S9A). The only colony that 
seemed to have the expected result was on lane 6. But the GSK3β.S9A fragment did not 
appear to have ~1.3 Kb when compared to the molecular marker – it seemed bigger. To 
solve this problem, the colony from lane 6 was digested with BamHI, which is expected to cut 
once in the MCS of pBSKS- and once inside the GSK3β.S9A sequence, theoretically 
resulting in two fragments with ~3.7 Kb and 0.6 Kb, if no recombination had occurred. Figure 
5 shows this result. 
 
 
 
 
 
 
Figure 5 – Digestion of colony 6 with BamHI restriction. Lane 1 – Molecular 
weight marker. Lane 2 – Colony 6 digested with BamHI. Lane 3 – Uncut 
colony 6.
 
 
The digestion of colony 6 with BamHI did not give the 2 expected bands in the gel (fig. 5), 
meaning that the ligation did not work as expected. Since none of the 10 selected white 
colonies had the expected vector, another method had to be planned to perform the 
subcloning of GSK3β.S9A in the #304. 
The alternative method thought was performing a PCR of pSG5.GSK3β.S9A with primers 
containing restriction sites for SphI (5’) and SalI (3’), GSK Fwd and GSK Rev, respectively, to 
clone in the TOPO vector (fig. S3).  This vector  was digested with the selected restriction 
enzymes and ligated in the #304 vector. The PCR reaction of pSG5.GSK3β.S9A was made 
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as described in the Methods, using 61ºC for annealing temperature and an extension time of 
2’30”. 
 
 
 
 
 
Figure 6 – Agarose gel at 1% showing the PCR reaction of 
pSG5.GSK3β.S9A. Lane 1 – Molecular weight marker. Lane 2 – PCR 
reaction of pSG5.GSK3β.S9A with selected primers. The  fragment 
within the red rectangle was purified. Lane 3 – PCR reaction without 
template. 
 
 
The Figure 6 shows the PCR of pSG5.GSK3β.S9A, which was highly specific as intended 
and produced just one band with the expected size of ~1.3Kb. This fragment was excised, 
purified and ligated in the TOPO vector, following the manufacturer’s instructions, and 
transformed into E. coli bacteria grown in Petri dishes prepared for colorimetric (lacZ based) 
and kanamycin selection. Five white colonies were selected and grown for minipreps, 
following a digestion with SphI and SalI restriction enzymes. Figure 7 shows the result of the 
digestion. 
 
 
 
 
Figure 7 - Digestion of the ligation of the GSK3β.S9A in 
TOPO vector evidenced in a 1% agarose gel 
electrophoresis.. Lane 1 – Molecular weight marker. Lanes 2-
6 – Selected colonies digested with SphI and SalI. The 
fragment within the red rectangle was purified. 
 
 
In Figure 7, lanes 2, 4, 5 and 6 seemed to have the fragments with the expected size. The 
fragment in lane 4 that contained  GSK3β.S9A shown within the red rectangle was chosen, 
purified and a ligation reaction with the #304.Ø vector previously digested with SphI and SalI 
was performed. JM109 bacteria were transformed with the ligation reaction and spread over 
a Petri dish prepared for ampicillin selection. Five colonies were selected from the Petri dish 
to prepare minipreps. To verify if the GSK3β.S9A gene was correctly inserted in the #304 
vector, a digestion with EcoRV and SalI was made. EcoRV is a ‘single cutter‘ in #304 vector 
and does not cut inside de GSK3β.S9A, being the expected bands of ~2.0Kb and ~7.8Kb. 
Figure 8 shows the digestion of the colonies with EcoRV and SalI. 
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Figure 8 - Digestion of the ligation of the GSK3β.S9A in 
#304.Ø vector evidenced in a 1% agarose gel 
electrophoresis.. Lane 1 – Molecular weight marker. Lanes 
2-6 – Selected colonies digested with EcoRV and SalI. 
 
 
All the colonies had the expected bands, except for the colony of lane 3 in Fig 8. This 
suggests that the #304.GSK3β.S9A vector was constructed. One positive colony was 
selected to be used for viral production. In addition, the DNA extracted from the miniprep was 
sequenced, and 293T cells were transfected to determined if the protein was correctly 
expressed. The 293T cells were transfected using Fugene 6 (Roche) according to the 
manufacturer’s instructions. One day post transfection, cells were lysed for protein extraction, 
resolved by 12% SDS-PAGE, and analysed for the expression of GSK3β by Western Blot. 
Figure 9 shows the Western Blot probed for Phospho-GSK3β, GSK3β, Actin and GFP. 
 
 
 
 
 
 
Figure 9 – Expression of GSK3b in 293T cells transfected with 
#304.GSK3β.S9A. Protein was detected by Western Blot analysis using 
antibodies against P-GSK3β, GSK3β, Actin and GFP. Lane 1 – Untransfected 
cells. Lane 2 – Fugene 6 transfected cells. 
 
 
It was expected from the probing in this Blot that GFP protein  was only detected in lane 2, 
an equal expression of Phospho-GSK3β in both lanes and an increased expression of total 
GSK3β in lane 2. All was according to the expected, except for the probing of total GSK3β. 
Lane 1 had only one band, corresponding to the endogenous GSK3β protein. However, lane 
2 showed two bands probing for GSK3β, which was puzzling. Could it be that the S9A 
mutation induced a shift in the Blot? This was unlikely. GSK3β has 46-47 kDa of molecular 
weight, corresponding to the lower band apparent in both lanes. The upper band was 
positioned at ~50 kDa, but one aminoacid change was very unlikely to cause such a great 
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shift in migration. Plus, the polyacrylamide gel was ran under denaturing conditions, so only 
the molecular weight of the peptide should influence migration, not the nature or structure of 
its aminoacids. So, the most likely explanation was that a mutation (in-frame insertion) 
occurred while the vector amplified in the bacteria. However, the sequencing results initially 
did not shed light on the problem. Sequencing data was checked against the coding 
sequence retrieved from the PubMed website with the reference NM_002093.2 in September 
2008. The analysis showed that the sequence of the GSK3β.S9A in the #304.GSK3β.S9A 
vector had the expected S9A mutation, but also a supposed in-frame deletion of 39 
nucleotides (nt911-nt949) that corresponded to 13 aminoacids. Paradoxically, instead of an 
insertion of nucleotides that could result in the observed increase of molecular weight of the 
protein, there seemed to be a deletion.  
To try and find a proper explanation for this discrepancy, a more thorough search was 
conducted in the PubMed website and the NM_002093.2 reference was checked in more 
detail. It was surprising to see that this reference had meanwhile been updated in March 
2009 and it redirected to the new reference NM_002093.3. This new reference indicated that 
the sequence retrieved belonged to the mRNA transcript variant 1, giving rise to GSK3β1.  
The other transcript variant (GSK3β2) was described as being 13 aminoacids shorter. After 
comparing the sequence of GSK3β2 with that of #304.GSK3β.S9A, the problem was partially 
solved: the cDNA used to construct the GSK3β.S9A mutant was retrieved from cells that 
expressed the transcript variant 2 (GSK3β2). However, this still did not explain how an 
isoform with less aminoacids could have a bigger molecular weight. We tried to look for an 
answer by carefully investigating the literature. Two articles were found describing GSK3β 
isoforms. The article by Mukai et al. [33] described the finding of the alternatively spliced 
exon (8b) containing the already mentioned 13 aminoacids. In this article, it was shown that 
the molecular weight of the 8b- isoform  was clearly below 50 kDa. The article by Schaffer 
and colleagues [32], also reported on exon 8b. Importantly, the authors further described the 
alternative splicing of exon 10 (nt1135-1234) of GSK3β, which corresponds to 33 
aminoacids. Although the work did not state the molecular weight of the GSK3β isoform that 
contained the exon 10, Western Blot data in the article, showed clearly a higher molecular 
weight  isoform, which contained exon 10. This isoform displayed a shift similar to the upper 
GSK3β band observed in Fig. 9. The puzzle was solved. It appears that 293T cells display an 
isoform of GSK3β that does not contain exon 10, whereas the cloned GSK3β.S9A gene 
includes exon 10 while lacking exon 8b. Isoforms containing exon 10 were found in all 
tissues analyzed by Schaffer et al (including lung, heart, liver, brain, etc). In conclusion, the 
GSK3β.S9A mutant cloned in the #304 vector was cloned from a functional GSK3β isoform 
and can be further used in experiments.  
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Cloning FOXO3a.A3 into the #304 vector and assessing its expression: 
The plan was to subclone the FOXO3a.A3 gene from the pECE.HA-FOXO3a.A3 (fig S4) 
vector to the #304.Ø vector. Similarly to the GSK3β.S9A cloning, the lack of adequate 
restriction sites in pECE, #304 or other intermediate vector and the difficulty of performing 
blunt-end ligations in the #304 vector, made us decide to delineate primers for PCR cloning 
with SphI (5’) and SalI (3’) restriction sites, HA Fwd and FOXO Rev, respectively, to ligate 
HA-FOXO3a.A3 in the TOPO vector. From the TOPO vector with the cloned FOXO3a.A3, 
digestions with SphI and SalI were performed and the FOXO3a.A3 mutant was ligated the 
#304 vector, thus cloning HA-FOXO3a.A3 into the #304 vector.  
The PCR reaction of pECE.HA-FOXO3a.A3 was made as described in the Methods, using 
61ºC for annealing temperature and an extension time of 2’30”. Figure 10, shows the result 
of this PCR. 
 
 
 
 
Figure 10 – Agarose gel at 1% showing the PCR reaction of pECE.HA-
FOXO3a.A3.  Lane 1 – Molecular weight marker. Lane 2 – PCR reaction  of 
pECE.HA-FOXO3a.A3 with selected primers. Lane 3 – PCR reaction without 
template. 
 
 
The expected size of the amplified fragment was ~2.1Kb. Lane 2 of Fig. 10 shows the 
amplification of a band with less than 2.0Kb size, which was not the band expected. This 
may have happened for two reasons: an annealing temperature too low may have directed 
the primers for unspecific annealing sites or the extension time may not have been enough. 
The processivity of the Pfu polymerase is ~1000bp.min-1. An extension time of 2’30” was 
expected to amplify up to 2.5Kb fragments, but maybe optimal conditions  were not achieved. 
We tried to surpass these two possible problems by repeating the PCR  with an annealing 
temperature of 63ºC and an extension time of 3’30”. Figure 11 shows the result of this PCR. 
 
 
 
 
 
Figure 11 – Agarose gel at 1% showing the PCR reaction of pECE.HA-
FOXO3a.A3.  Lane 1 – Molecular weight marker. Lane 2 – PCR reaction  of 
pECE.HA-FOXO3a.A3 with increased annealing temperature and extension 
time. Lane 3 – PCR reaction without template. 
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However, the increased annealing temperature and extension time did not solve the 
problem, as shown in Lane 2 of Figure 11. The unspecific band displayed in Fig. 10 
continued to be amplified. Another possible solution came from the fact that in the pECE 
vector there might have been very similar sequences to the template of one of the primers 
that  caused unspecific amplification. Therefore, the new strategy was to cut the vector with a 
restriction enzyme that excised a fragment containing the HA-FOXO3a.A3 gene, ran the 
digestion in a gel to have the fragment purified and then made a PCR reaction from this 
fragment avoiding the unspecific annealing. The selected restriction enzyme was SphI. From 
its digestion, a fragment with ~2.7Kb of size containing the HA-FOXO3a.A3 gene and a little 
part of the pECE was obtained and purified. A PCR reaction in the same conditions as the 
previous one was performed.  
 
 
 
 
 
 
 
Figure 12 – Agarose gel at 1% showing the PCR reaction of a fragment 
excised from the pECE vector containing the HA-FOXO3a.A3 gene.  
Lane 1 – Molecular weight marker. Lane 2 – PCR reaction of the 
fragment containing HA-FOXO3a.A3. Lane 3 – PCR reaction without 
template. 
 
Figure 12 shows the result of the PCR reaction. In Lane 2, rather than the expected specific 
band, a smear with a few stronger bands could be seen. Another problem may have been 
the primers used, particularly the forward primer which contained the HA-tag sequence. More 
than one nucleotide sequence could have originated from the same aminoacid sequence. 
So, when the HA Fwd primer was firstly designed, an Internet search in several companies’ 
websites was made to find the most common nucleotide sequence for HA-tag, since the 
sequence present in the pECE vector was not available. Possibly, the HA sequence in the 
HA Fwd primer was not the correct one. Then, a new primer with another very common HA-
tag sequence was ordered (HA new). The PCR reaction with the new primer was made with 
an annealing temperature of 62ºC and an extension time of 3’30”. Unfortunately, the PCR 
continued to amplify a band with the size seen in Fig 11. After this unsuccess, the HA-tag 
was discarded and a new forward primer was designed to amplify only the FOXO3a.A3 
gene. 
A new PCR reaction was set with an annealing temperature of 61ºC and an extension time 
of 3’30”. Figure 13 shows the result of this PCR. 
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Figure 13 – Agarose gel at 1% showing the PCR reaction of pECE.HA-
FOXO3a.A3 vector with FOXO Fwd and Rev primers.  Lane 1 – Molecular weight 
marker. Lane 2 – PCR reaction showing the expected band within the red 
rectangle.  
 
 
Lane 2 of Fig 13 shows that finally the PCR amplified the ~2.1Kb expected band, seen 
within the red rectangle. This band was then excised from the gel, purified, ligated in the 
TOPO vector and DH5α E. coli were transformed and grown in Petri dishes prepared for 
colorimetric (lacZ based) and kanamycin selection. However, no colonies of bacteria could 
be grown in the plates, which suggested that the ligation in the TOPO vector was not 
occurring even after several attempts.  
After an extensive search for possible solutions to clone FOXO3a.A3, a new cloning kit was 
found: the pGC.Blue cloning kit from Lucigen Corporation. This kit works based in CG 
cloning as opposed to TOPO that works based in TA cloning. The GC cloning was the 
reason to choose this kit over other kits similar to TOPO, because generally a GC interaction 
is stronger than a TA interaction and also because FOXO3a.A3 was a GC rich gene (>60% 
GC content) which could have affected the TA cloning. After the ligation reaction with this 
new kit was performed, 10G E. coli were transformed and grown in Petri dishes prepared for 
colorimetric (lacZ based) and kanamycin selection. Seven white colonies plus one blue 
colony (negative control) were picked for minipreps. The minipreps DNA were extracted and 
a digestion with SphI and SalI was performed. Figure 14 shows the result of the digestion. 
 
 
Figure 14 - Agarose gel at 1% showing the digestion of the ligation of the FOXO3a.A3 in pGC.Blue vector. 
Lanes 1 and 11 – Molecular weight marker. Lanes 2-8 – Selected white colonies digested with SphI and SalI. The 
fragment within the red rectangle was purified Lane 9 - #304.Ø digested with SphI and SalI. The fragment within 
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the red rectangle was purified. Lane 10 – Digestion of a blue colony with SphI and SalI as a negative cloning 
control. 
 
In theory, a digestion of the pGC.Blue vector with the FOXO3a.A3 gene cloned in it with 
SphI and SalI restriction enzymes should have resulted in 4 fragments: 48bp (not visible), 
~0.9Kb and ~1.2Kb that belonged to the vector and ~2.1Kb, the FOXO3a.A3 gene. In fig 14 it 
can be seen that lanes 3, 5, 7 and 8 had the expected restriction pattern, this showed that 
FOXO3a.A3 was finally cloned in an intermediate vector. The fragments highlighted by the 
red rectangles, FOXO3a.A3 and digested #304, were purified and a ligation reaction 
performed as described in the Methods. JM109 E. coli were transformed as described and 
grown in Petri dishes prepared for ampicillin selection. In this first attempt no colonies grew in 
the plate. This could have been because the insert-to-vector ratio was not optimized for this 
vector, although this ligation followed the 3:1 insert-to-vector ratio based on size. Therefore, 
a new ratio of 1:1 (insert:vector) based on the weight of the DNA was attempted. Again, no 
colonies formed in the Petri dish. 
Looking at the troubleshooting of the datasheet from the reagents (Fermentas) and bacteria 
(Stratagene) used in the ligation reaction, an experiment for optimization of ligation and 
transformation was devised (Table 1), where all the other settings were kept as described in 
Methods: 
A 
2H LIGATION 
+2ΜL PEG, +0.8ΜL Β-ME 
B +2μL PEG, - β-ME 
 
Table 1 - Testing of two different conditions (A and B) to optimize the ligation of FOXO3a.A3 in #304. The 
variables changed are time of ligation reaction, addition of PEG and addition of beta-ME to the bacteria prior to 
transformation.
 
In sticky-end ligations with the presence of 2μL PEG 4000 at 50%, the maximum 
recommended duration of the reaction was 2 hours. For the transformation of bacteria 0.8μL 
of β-ME at 1,4M was added/not added to the thawed aliquot on ice, followed by a resting of 
10min and the addition of the DNA.  
After performing these two different conditions, bacteria were grown in Petri dishes 
prepared for ampicillin selection. Colonies were selected for minipreps and DNA extraction, 
followed by  a digestion with SphI and SalI. Figure 15 shows the result of the digestion. 
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Figure 15 - Agarose gel at 1% showing the digestion of the ligation of the FOXO3a.A3 in #304 vector. Lanes 1 
and 14 – Molecular weight marker. Lanes 2-6 – Digestion with SphI and SalI of selected colonies from condition 
A. Lanes 7-12 - Digestion with SphI and SalI of selected colonies from condition B. Lane 13 – Digestion of 
pGC.Blue.FOXO3a.A3 with SphI and SalI as a FOXO3a.A3 positive control. 
 
Four colonies had the expected fragments of ~2.1Kb and ~8.6Kb for FOXO3a.A3 and 
#304.Ø, respectively: Lanes 4, 5, 6 and 11. This suggested that the #304.FOXO3a.A3 vector 
was finally constructed. The colony corresponding to lane 4 was selected for viral production. 
The DNA extracted from the maxiprep was sequenced and 293T cells were transfected in 
order to determine if the protein was correctly expressed. 
The 293T cells were transfected using Fugene 6 according to the manufacturer’s 
instructions. One day post transfection, cells were lysed for protein extraction and resolved 
by 12% SDS-PAGE, and analysed by Western Blot. Figure 16 shows the expression of 
Phospho-FOXO3a, FOXO3a and GFP. 
 
Figure 16 – Western Blot of a 12% polyacrylamide gel showing the 
expression of P-FOXO3a (Upstate), FOXO3a (Upstate) and GFP. Lane 1 – 
Untransfected 293T cells. Lane 2 – Fugene 6 transfected 293T cells with 
#304.Ø. Lane 3 – Fugene 6 transfected 293T cells with #304.FOXO3a.A3. 
Lane 4 – Wild type HPB cells 
 
 
In Lane 3 the over expression of FOXO3a.A3 was clearly seen, showing that the 
FOXO3a.A3 gene was correctly expressed. Moreover, the integrity of the FOXO3a.A3 gene 
was confirmed by the sequencing results. In conclusion, the #304.FOXO3a.A3 vector can be 
further used in experiments.  
 
Production of lentiviruses and transduction of HPB-ALL and TAIL7 cells.  
In order to start fulfilling the main objective of this chapter, lentiviruses had to be produced 
in high titers. The cell line 293T was used as a packaging cell line for lentivirus production, 
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calcium chloride transfection of all the necessary plasmids, as described in the Methods. 
Viruses were then harvested and stored for later use. After the last harvest, cells were 
washed and analyzed by Flow Cytometry to assess the efficiency of transfection. The 
supplementary Figure S6, shows a typical result of the transfection efficiency, higher than 
90%. During the traineeship, many viral productions were made. The titers varied usually in 
the range of 1*105 to 9*105 viral particles/mL. After concentration, the viral titer increased, in 
average, 1 to 1.5 log. For a transduction experiment, two or three viral productions were 
used. 
 
Effects of GSK3β.S9A and FOXO3a.A3 in IL7-mediated effects in T-ALL cells: 
HPB-ALL transductions were performed as described in the Methods section. The yield of 
these transductions was disappointing, with percentages of GFP+ cells ranging from 5-12%. 
After the transduction, HPB-ALL cells were incubated to assess survival. Cells were stained 
for flow cytometry with AnnexinV-APC and 7AAD, which allow for a sensitive determination 
of viability of lymphocytes, including T-ALL cells. It should be noted that the data were 
acquired by first gating in the “live” cell population as determined by FSC x SSC distribution, 
and subsequent subgating in the GFP+ cells. This implicates that we analyzed the effects on 
viability of cells that were still expressing GFP (excluding all those that may have lost GFP 
expression as a consequence of the cell death process). The reason for this approach was 
that we did not want to bias our analysis by including non-transduced cells. On the other 
hand, this implicates that we could only compare viable cells versus early apoptotic cells, and 
that most of the cells included in the gate were a priori mostly viable. Nonetheless, we found 
that the presence of constitutively active FOXO3a resulted in a general lowering in viability, 
both at 48h (data not shown) and 72h (Figure 17). At 48h IL-7 boosted the viability of empty 
transduced cells and could partially rescue the viability of the FOXO3a.A3 transduced cells 
(not shown). However, at 72h IL-7 was no longer able to rescue the viability of FOXO3a.A3 
transduced cells, while it still was able to rescue the viability of empty transduced cells (Fig 
17).  
The strategy we used resulted in a great loss of information about the late 
apoptotic/necrotic cells. Therefore, the next step taken will be to sort the GFP+ cells and then 
perform this same experiment using the different constructs (#304-Empty, #304-GSK3β.S9A 
and #304-FOXO3a.A4). 
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Figure 17 – Viability assay of HPB-ALL transduced with the empty vector or FOXO3a.A3 bearing vector. Cells 
were cultured with or without IL-7 for 48h (A) and 72h (B). Stainings for TMRE, AnnexinV-APC and 7AAD were 
made. For each time point graphics are shown with the proportion of live (AnnV-7AAD-), very early apoptotic 
(TMRE-), early apoptotic (AnnV+7AAD-) and late apoptotic (AnnV+7AAD+) cells. Error bars from 3 replicates are 
presented. 
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RESULTS AND DISCUSSION – CHAPTER 2: 
Regulation of the Tumor Suppressor PTEN 
The Therapeutic Potential of Combined γ-secretase and CK2 Inhibition in T-ALL  
 
As already discussed, in T-ALL PTEN expression and activity can be downregulated by two 
independent processes, Notch1 and CK2 activation, respectively. Therefore, an interesting 
hypothesis to test was if the combined inhibition of Notch and CK2 could have an impact on 
the proliferation and viability of T-ALL cells. Experiments with the PTEN positive cells lines 
HPB-ALL, TAIL7 and TALL-1 were performed as described and cell size, cell counts and 
proliferation assays were made.  
Incubation with the γ-secretase (i.e., Notch) inhibitor DAPT, or with the CK2 inhibitors 
DRB/TBB, lowered the total cell counts of cultured HPB and TAIL7 cells when compared to 
medium alone (Figure 18). This effect was further enhanced by the combined presence of 
both types of inhibitors, which suggested a cooperative effect of Notch and CK2 inhibition as 
potentiators of PTEN’s activity. Further strengthening this result was the cell size 
measurement, an indirect indicator of the cells’ metabolic activity that is also associated with 
cell cycle stage [5, 12] . HPB-ALL and TAIL7 cells were consistently smaller (thus, likely non-
activated, quiescent) when cultured with one inhibitor, and even less when cultured with both 
inhibitors (Fig 19). Additionally, proliferation of HPB-ALL, TAIL7 and TALL1 cell lines, 
assessed by incorporation of 3H-thymidine during DNA synthesis, was greatly diminished in 
the presence of the inhibitors, particularly when used in combination (fig 20). The reason for 
the cooperative effects of these inhibitors likely rely on the fact that they converge on the 
regulation of PTEN by different, and complementary, mechanisms. On one hand, γ-
secretase inhibitors, by inhibiting Notch, increase the protein level of PTEN via transcriptional 
upregulation; on the other hand, inhibition of CK2 prevents the CK2-mediated 
posttranslational inactivation of PTEN, by making the PTEN less stable but more active. The 
use of both inhibitors has the potential to more effeciently block the PI3K/Akt pathway (Fig 1). 
Altogether, our results suggest that the combined administration of γ-secretase inhibitors and 
CK2 inhibitors might have therapeutic potential in T-ALL. 
These data, along with other results, were accepted for publication in Haematologica as a 
manuscript entitled: "Regulation of PTEN by CK2 and Notch1 in primary T-cell acute 
lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase 
inhibitors".. 
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Figure 18 – The γ-secretase inhibitor DAPT and CK2 inhibitors DRB/TBB act cooperatively to decrease the total 
cell number of T-ALL cells. Cells were counted in triplicates after 4 days (A – HPB-ALL) or 7 days (B – TAIL7) of 
culture. Viable number of cells was assessed in a hemocytometer by trypan blue exclusion. * p<0.05, ** p <0.01, 
*** p <0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 – Upon treatment, the γ-secretase inhibitor DAPT and CK2 inhibitors DRB or TBB act synergistically 
to decrease the cell size. Cell size was assessed by Flow Cytometry in triplicates after 72h of culture. A – HPB-
ALL cells; B – TAIL7 cells. 
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Figure 20 – Proliferation is reduced when cells are treated with the γ-secretase inhibitor DAPT and CK2 
inhibitors DRB or TBB. Cells were cultured for 7 days in triplicates. 16h prior to analysis cells are incubated with 
3H-Thymidine. A – TAIL7 cells; B – TALL-1; C – HPB-ALL cells. * p<0.05, ** p <0.01, *** p <0.001. 
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CONCLUSIONS 
 
This thesis aimed to explore two complementary issues important for leukemia progression: 
the signals from the miroenvironment, here represented by IL-7, and the molecular 
aberrations occurring within the cancer cell, here represented by CK2 and Notch, both of 
which converge upon PI3K/Akt pathway. In the first case, we planned to evaluate the role of 
GSK3 and FOXO3a on IL-7-mediated effects in T-ALL. In the second case, we planned to 
determine the therapeutic potential of simultaneously inhibiting Notch and CK2 activity in T-
ALL cells. 
The objectives of the first chapter of the thesis were only partially achieved. Despite the 
many obstacles, the FOXO3a.A3 and GSK3β.S9A mutants were subcloned into the #304 
lentiviral vector. Their expression, assayed in 293T cells, was correct and they were not 
phosphorylated. The preliminary data obtained in the functional experiments with HPB-ALL 
was highly suggestive that at least FOXO3a inhibition was mandatory for IL-7 mediated 
survival and proliferation of T-ALL cells lines.  
The objectives of the second chapter of the thesis were totally achieved. We demonstrated 
that the use of γ-secretase inhibitors combined with CK2 inhibitors, lead to a cooperative 
negative effect on T-ALL cell number, cell size and proliferation.  
In conclusion, the work here developed has in part contributed to the potential opening of 
new therapeutic strategies and may lead to a better characterization of PI3K/Akt pathway in 
the context of T-ALL. 
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SUPPLEMENTARY INFORMATION
 
 
 
 
 
 
Figure S1 – Circular map of pSG5 and its characteristics. The 
GSK3β.S9A gene is cloned in the EcoRI/∆SmaI-∆MBamHI 
restiction sites. Adapted from Statagene’s pSG5 datasheet.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2 – A – pBSKS
-
 circular map, its characteristics and B – MCS detail. Adapted from Stratagene’s pBSKS
-
 
datasheet.  
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Figure S3 – Circular map of TOPO vector with its characteristics and MCS detail. Adapted from Invitrogen’s 
datasheet. 
 
 
 
 
 
 
Figure S4 – Circular map of pECE. HA-FOXO3a (not FOXO3a.A3) vector with its characteristics. The bigger blue 
ORF represents the place where, in a equivalent way, HA-FOXO3a.A3 is cloned. Adapted from Addgene website:  
http://www.addgene.org. 
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Figure S5 – Circular map of the #304.deltaLNGFr vector ant its characteristics. The #304.Ø vector was 
reconstructed by the excision of the delta LNGFr fragment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6 – Representative result of transfection efficiency of 293T cells obtained by the calcium phosphate 
method. Over 90% of the cells are transfected by the #304 based vectors. Assessed by flow cytometry for the 
presence of GFP.  
 
 
